TwitterLinkedInYoutubeSlideshareflickrIFPMA - Global Health Matters - BlogRSS
IFPMA Home

International Federation of Pharmaceutical Manufacturers & Associations



The IFPMA 2014 Interview Series

The IFPMA Interview Series is a video library of interviews with people from different walks of life talking about topics that are in a way or another related to the industry. The series are about understanding the issues concerning the various IFPMA portfolio-holders and stakeholders; how they perceive those issues as and how they relay the information about these. The IFPMA draws on a wide array of communication strategies and resources to produce a video interview that is easily accessible, well-illustrated with a wealth of information relevant to our different audiences. It is all about asking the intelligent questions our audience would be asking to dig deeper with IFPMA staff and stakeholders and understand better what’s at stake for the different portfolio holders operating in the industry environment and at IFPMA.

It is a unique interview show prepared in advance that starts with thorough research and ends with a rich exchange that can be an eye opener to the industry world. It’s not meant to be a tool for corporate posturing. It’s about intelligent interview based on challenging questions. We take the time to dig deeper with our guests. To offer them space where wordsmithing is not our first worry. The format we chose is short, does not exceed 4 minutes, up to the point and above all people centred.

We hope you enjoy it and if you have any questions or queries regarding this tool, please send it to Ms Sadia Kaenzig : S.Kaenzig(at)ifpma.org

 

 

 

Interview with Dr Fermin Ruiz de Erenchun, IFPMA Biotherapeutics Group Committee Chair & Global Head Biologic Strategy Team at Roche

In this interview, Dr Fermin Ruiz de Erenchun explains how access to biotherapeutic products, including biosimilars, and ensuring their quality, safety and efficacy will be important challenges in the future, namely in Latin America. Science-based regulatory standards for medicines, in alignment with World Health Organization (WHO) guidance, are essential to ensure patient safety, and implementation of these standards at the national level will be critical moving forward.

Biotherapeutics are typically derived from living organisms. They are made by genetically engineering DNA, and a high level of precision is required in the commercial manufacturing process to produce a consistent product each time. Every step we take in the production of these medicines requires highly controlled testing to ensure consistent quality, safety, and efficacy.

As President and General Manager of Pfizer's Vaccines and an IFPMA Vaccine CEO Steering Committee member, Ms Susan Silbermann talks about why investing in vaccines is so valuable and how the effective introduction and rollout of new vaccines can save millions of more lives.

In this video, Mr Andrew Jenner, IFPMA’s Executive Director, Corporate Strategy & Legal Affairs, gives the pharmaceutical industry perspective on innovation.

Dr Laetitia Bigger talks about the Industry Contribution to Global Vaccine & Immunization Research Forum.